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Increasing evidence links the gut microbiota with
colorectal cancer. Metagenomic analyses indicate
that symbiotic Fusobacterium spp. are associated
with human colorectal carcinoma, but whether this
is an indirect or causal link remains unclear. We find
that Fusobacterium spp. are enriched in human
colonic adenomas relative to surrounding tissues
and in stool samples from colorectal adenoma and
carcinoma patients compared to healthy subjects.
Additionally, in theApcMin/+mousemodel of intestinal
tumorigenesis, Fusobacterium nucleatum increases
tumor multiplicity and selectively recruits tumor-infil-
trating myeloid cells, which can promote tumor
progression. Tumors from ApcMin/+ mice exposed to
F. nucleatum exhibit a proinflammatory expression
signature that is shared with human fusobacteria-
positive colorectal carcinomas.However, unlikeother
bacteria linked to colorectal carcinoma, F. nucleatum
does not exacerbate colitis, enteritis, or inflamma-
tion-associated intestinal carcinogenesis. Collec-
tively, these data suggest that, through recruitment
of tumor-infiltrating immune cells, fusobacteria
generate a proinflammatory microenvironment that
is conducive for colorectal neoplasia progression.
INTRODUCTION
There is accumulating evidence that members of the gut micro-
biota contribute to colorectal cancer, the second most occuring
cancer worldwide (Jemal et al., 2011). The majority of studies
have focused on a small subset of colorectal cancers, colitis-
associated colorectal cancers, and employed rodent preclinicalCell Hosmodels. Antibiotic treatment or absence of the gut microbiota
reduced tumor incidence in several murine colitis-associated
colorectal cancer models (Garrett et al., 2009; Uronis et al.,
2009). Recently, two bacterial pathogens have been identified
that promote colitis-associated colorectal cancer. Enterotoxi-
genic Bacteroides fragilis induces colitis and colonic tumors in
ApcMin/+ mice by triggering a T helper type 17 (Th17) inflamma-
tory response (Wu et al., 2009), while adherent-invasive Escher-
ichia coli strain NC101 promotes colitis-associated colorectal
cancer in monocolonized, azoxymethane-injected Il10/ mice
(Arthur et al., 2012). However, the majority of human colorectal
cancers do not arise in the setting of inflammatory bowel disease.
The gut microbiota may be a driver in colorectal cancers that
are not associated with colitis. Metagenomic analyses using
whole-genome sequencing (Kostic et al., 2012), transcriptome
sequencing (Castellarin et al., 2012), or bacterial 16S ribosomal
RNA (rRNA) gene DNA sequencing (Kostic et al., 2012; Marchesi
et al., 2011) have shown enrichment of Fusobacterium species in
colorectal cancers relative to adjacent normal tissue. However, it
has been unclearwhether these findings represent an indirect as-
sociation orwhetherFusobacterium spp. functionally contributes
to colorectal cancer (CRC) tumorigenesis (Tjalsma et al., 2012).
Here, we assess the association of F. nucleatum in stool and
colonic tissue from patients with colorectal adenomas and ade-
nocarcinomas andanalyze the effect ofF. nucleatumon intestinal
cancer progression and tumor inflammation in mouse models.
Our data are consistent with the possibility that F. nucleatum
potentiates noncolitis-associated intestinal tumorigenesis.RESULTS
Fusobacteria Are Enriched in Colonic Adenomas and
Stool Samples from Patients with Adenomas and
Colorectal Carcinomas
Colonic adenomas are neoplastic epithelial lesions that can
becomemalignant and are precursors of themajority of sporadict & Microbe 14, 207–215, August 14, 2013 ª2013 Elsevier Inc. 207
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Figure 1. Fusobacterium Is Enriched in Adenoma versus Adjacent
Normal Tissue and Detected at a Higher Abundance in Stools from
CRC and Adenoma Cases than from Healthy Controls
(A) Fusobacterium abundance for normal tissue (x axis) versus adenoma
(y axis) is plotted. A total of 29 matched adenoma normal tissue pairs were
tested. Each symbol represents data from one patient (adenoma and normal
tissue).
(B) Fecal Fusobacterium abundance from healthy subjects (n = 30), subjects
with colorectal adenomas (n = 29), and colorectal cancer (n = 27). See also
Table S1.
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Fusobacterium Potentiates Intestinal Tumorigenesiscolorectal cancers. Given the enrichment of Fusobacterium spp.
in colorectal tumors versus adjacent normal tissue, we examined
if there was a similar enrichment in adenomas, suggesting the
involvement of Fusobacterium in neoplastic initiation or progres-
sion, prior to the establishment of carcinoma. A few recent
studies have performed case-control studies of colorectal ade-
nomas using 16S rRNA gene surveys, with one noting fusobac-
terial enrichments in their patient cohort (McCoy et al., 2013;
Sanapareddy et al., 2012; Scanlan et al., 2008; Shen et al.,
2010). We measured Fusobacterium spp. abundance in paired
adenoma tissue versus adjacent normal tissue from the same
patient drawing samples from several geographic locations
and registries: the Cooperative Human Tissue Network (Eastern,
Southern, and Western divisions of the United States), Massa-208 Cell Host & Microbe 14, 207–215, August 14, 2013 ª2013 Elsevichusetts General Hospital, and the University of Aberdeen
School of Medicine. None of these patients had a history of
inflammatory bowel disease (IBD). We found that Fusobacterium
was detectable by quantitative PCR (qPCR) in 48%of adenomas
(n = 29); in those cases that were positive, Fusobacterium was
enriched in adenomas relative to surrounding tissue (p < 0.004)
(Figure 1A and Table S1 available online). These data suggest
that Fusobacterium begins to accumulate at early stages of
colonic tumorigenesis in some groups of patients.
Next, we determinedwhether fusobacteria have a higher over-
all abundance in the fecal microbiota of CRC patients relative to
healthy controls in a case-control experiment. We compared the
levels of Fusobacterium spp. to levels of a universal eubacteria
16S rRNA gene amplicon by qPCR of the stool. Subjects pro-
vided their stool samples to the Early Detection Research
Network (EDRN) prior to bowel preparation and screening colo-
noscopy and had no prior history of colorectal cancer or gastro-
intestinal disease (Figure 1B and Table S1). Fusobacterium spp.
were enriched in CRC patients (p < 13 105) as well as in stools
from subjects with adenomas as compared to healthy controls
(p < 53 103). These results indicate that increased abundance
of Fusobacterium species in the gut microbiota may be a general
feature of colonic tumorigenesis.
Fusobacterium nucleatum Promotes Intestinal
Tumorigenesis
The enrichment of Fusobacterium spp. in colorectal adenomas
and the previously reported enrichment in colorectal carcinomas
(Castellarin et al., 2012; Kostic et al., 2012; Marchesi et al., 2011)
prompted us to examine whether Fusobacterium could acc-
elerate tumorigenesis in mice. We utilized mice that develop in-
testinal tumors because of a mutation in one copy of the tumor
suppressor gene Apc (C57BL/6 ApcMin/+) or genetic defects
that result in chronic intestinal inflammation (BALB/c Il10/
and BALB/c T-bet/ 3 Rag2/). We introduced human iso-
lates of F. nucleatum, Streptococcus species (S. anginosus,
S. parasanguinis, and S. sanguinis; n = 4 mice per strain), or
tryptic soy broth (TSB) to ApcMin/+ mice and F. nucleatum or
TSB to IL10/ and T-bet/ 3 Rag2/ mice. Streptococci
were used as control strains because of the longstanding
association of streptococcal species with occult colonic
malignancies.
Introduction of F. nucleatum into ApcMin/+ mice accelerated
the onset of colonic tumors. ApcMin/+ mice fed F. nucleatum
developed a significantly higher number of colonic tumors as
compared to ApcMin/+ mice fed Streptococcus (Strep.) spp., or
TSB (p < 0.001, p < 0.0001) (Figures 2A–2C). However,
F. nucleatum did not induce colitis (Figures 2A–2C), in contrast
with enterotoxigenic Bacteroides fragilis, which causes colitis
and accelerates tumorigenesis in ApcMin/+ mice (Wu et al.,
2009). Also, F. nucleatum neither exacerbated intestinal inflam-
mation nor accelerated tumorigenesis in the two mouse models
of colitis-associated colorectal cancer examined (Figure 2A).
Consistent with prior findings in human colorectal carcinoma
(Castellarin et al., 2012; Kostic et al., 2012), F. nucleatum was
culturable from ApcMin/+ tumors and enriched in tumor tissue
relative to adjacent normal tissue in F. nucleatum-fed ApcMin/+
mice as assayed by qPCR (Figure 2D) and fluorescence in situ
hybridization (FISH) using a Fusobacterium 16S rRNA-directeder Inc.
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Figure 2. Fusobacterium nucleatum Promotes Small and Large Intestinal Tumorigenesis and Is Enriched in Tumor Tissues of ApcMin/+Mice
(A) Colon tumor counts and histologic colitis scores from ApcMin/+, Il10/, and T-bet/3 Rag2/mice fed F. nucleatum (F. nuc), Streptococcus spp., or TSB
control. Mice were started on the 8-week feeding regimen at 6 weeks of age.
(B and C) Representative images of colons (ruler numbers in cm) (B), and colonic histological analysis of ApcMin/+ mice (100 mm scale bar) (C).
(D) Fusobacterium abundance in matched tumor (T) versus normal (N) tissues from colons of ApcMin/+ mice fed F. nucleatum measured by qPCR.
(E) Representative FISH images of colonic tumor andmatched normal colonic tissue from an ApcMin/+mouse fed F. nucleatum using a Fusobacterium 16S rDNA-
directed probe (50 mm scale bar).
(F and G) Small intestinal aberrant crypt foci, adenoma, and adenocarcinoma counts (F), and histologic enteritis scores in ApcMin/+ mice fed F. nucleatum,
Streptococcus species, or TSB control (G).
(H) Representative sections of small intestines from ApcMin/+ mice (ruler numbers in cm). ***p < 0.0001, **p < 0.001, *p < 0.01. See also Figure S1.
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Fusobacterium Potentiates Intestinal Tumorigenesisprobe (Figure 2E). However, we did not observe an overall
increase in bacterial tumor load in F. nucleatum-fed ApcMin/+
mice (Figure S1).Cell HosApcMin/+ mice fed F. nucleatum also had a significantly higher
count of small intestinal aberrant crypt foci (ACF), adenomas,
and adenocarcinomas as compared to Strep. spp.- or TSB-fedt & Microbe 14, 207–215, August 14, 2013 ª2013 Elsevier Inc. 209
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Figure 3. F. nucleatum Selectively Expands Myeloid-Derived Immune Cells, but Not Lymphoid Immune Cells in the Intestinal Tumor Micro-
environment
Multicolor flow cytometric analyses.
(A) Percentage (left panel) with representative density plots and the number (right panel) of intratumoral myeloid cells and lymphoid cells. Data for CD11b+myeloid
cells, CD3+CD4+ T cells, or CD3+CD8+ T cells are shown. Mean percentages ± SEM are shown within each plot. n = 6, 4, or 15 for not treated, S. sanguinis, or
F. nucleatum. ***p < 0.001, **p < 0.01, *p < 0.05.
(B) A schematic of the gating strategy for subset identification of intratumoral myeloid cells. Representative density plots of myeloid cells are shown. The initial
analysis region used CD11b versus Gr-1 to identify CD11b+Gr-1+ MDSC population (violet boxes) and CD11b+Gr-1macrophage population (light green boxes).
Arrows show the gating progression used to discriminate the nine subsets. Each number on the density plot represents the corresponding subset ofmyeloid cells.
(C) Cell number/gram of tumor for myeloid cells from the treatment groups. Each symbol represents data from an individual mouse. See also Figure S2.
Cell Host & Microbe
Fusobacterium Potentiates Intestinal Tumorigenesiscontrols. In addition, we did not observe any small intestinal en-
teritis in thesemice (Figures 2F–2H). Together, these results indi-
cate that F. nucleatum may accelerate tumorigenesis in the
absence of enteritis or macroscopic inflammation, in ApcMin/+
mice.
F. nucleatum Selectively Expands Myeloid-Derived
Immune Cells
Immune cells and their effectors are key components of tumors
and promote neoplastic progression. To address whether
F. nucleatum contributes to tumorigenesis by affecting intratu-
moral immune cells, we characterized tumor-infiltrating immune
cells from the intestinal tumors of ApcMin/+ mice that were fed
F. nucleatum or S. sanguinis for 8 weeks or were not fed bacteria
over the same time frame. Small intestinal, rather than colonic,
tumors were used because controls did not develop sufficient
numbers of colon tumors within the experimental time frame.210 Cell Host & Microbe 14, 207–215, August 14, 2013 ª2013 ElseviWeobserved an increase in infiltrating cells of themyeloid line-
age in the tumors from Fusobacterium-treated mice. CD11b+
myeloid cells increased (mean 3.23 higher cell number, mean
4.03 higher percent population) in the tumors of ApcMin/+ mice
fed F. nucleatum as compared to controls, while numbers of
CD3+CD4+ and CD3+CD8+ T lymphocytes were not significantly
different (Figure 3A).
Differentiated CD11b+ myeloid cells, such as macrophages,
dendritic cells (DCs), and granulocytes, play an important role
in promoting tumor progression and angiogenesis (Coussens
and Pollard, 2011). Thus, we defined the different subsets of
tumor-infiltrating myeloid cells by multicolor flow cytometry
using a gating strategy that employed nine cell-surface mole-
cules (Figure 3B) as well as functional properties, including argi-
nase-1 and inducible nitric oxide synthase (iNOS) expression
and T cell suppressive activity (Figure S2). Myeloid-derived sup-
pressor cells (MDSCs) are tumor-permissive myeloid cells wither Inc.
Cell Host & Microbe
Fusobacterium Potentiates Intestinal Tumorigenesispotent immune suppressive activity (Gabrilovich et al., 2012).
MDSCs were enriched (mean 3.73 increased cell number) in
F. nucleatum-fed mice versus controls (Figure 3C). There are
two principal MDSC subsets, monocytic (M-MDSC) and granu-
locytic (G-MDSC), both of which increased in the tumors of
F. nucleatum-fed mice (M-MDSCs, mean 6.73 increased cell
number; G-MDSCs, mean 8.93 increased cell number)
compared to controls (Figure 3C). These MDSC subsets sup-
press CD4 T cells predominantly via expression of arginase-1
and iNOS (Gabrilovich and Nagaraj, 2009). Consistent with pub-
lished phenotypes (Gabrilovich and Nagaraj, 2009), M-MDSC
expressed higher levels of arginase-1 and iNOS than
G-MDSC (Figure S2A). Additionally, MDSC showed significant
T cell suppressive activity (Figure S2C). Recent studies support
that tumor-associated neutrophils (TANs) play a role in tumor
progression and angiogenesis and in the modulation of the anti-
tumor immunity (Mantovani et al., 2011). We found that
numbers of granulocytes and TANs increased by a mean of
13.43 in tumors from F. nucleatum-fed mice compared to con-
trols (Figure 3C).
Substantial experimental data from clinical and preclinical
studies indicate that tumor-associated macrophages (TAMs)
promote tumor progression and metastasis (Mantovani and
Sica, 2010; Qian and Pollard, 2010). Both TAMs and M2-like
TAMs were enriched in F. nucleatum-fed mice as compared
to controls (mean 7.83 and 50.83 increased cell number,
respectively) (Figure 3C). TAMs inhibit T cell responsiveness
via expression of arginase-1 (Ruffell et al., 2012). M2-like TAMs
had arginase-1 levels 2-fold higher than that of to TAMs and
exhibited significant suppressive activity on CD4 T cells (Figures
S2B and S2C).
Within tumors, DCs can either dampen or promote antitumor
immunity (Mellman et al., 2011). The intestine possesses a spe-
cific subset of DCs expressing CD103 integrin. These cells play a
role in the regulation of immune responses by promoting the
expansion of Foxp3+ regulatory T cells, a CD4+ T cell subset
that suppresses cytotoxic and effector T cells, and thus dampen
antitumor immunity (Coombes et al., 2007; Josefowicz et al.,
2012). We observed that numbers of conventional DCs were
increased in tumors from F. nucleatum-fed mice (mean 8.43
higher cell number) and found increases in classical myeloid
DCs and CD103+ regulatory DCs (mean 4.53 and mean 6.93
increased cell number, respectively) compared to tumors from
control mice (Figure 3C). To determine whether the changes in
TAMs, MDSCs, and DCs were affecting CD4+ T cell subsets
implicated in colon tumorigenesis (Grivennikov et al., 2012), we
examined both intratumoral Th17 cells and CD4+ Foxp3+ reg-
ulatory T cells. While there was a trend toward an increase
in Foxp3+ regulatory T cells (Treg) and Th17 cells in
F. nucleatum-fed mice, there was significant heterogeneity
within this group that did not correlate with intratumoral
F. nucleatum abundance, and differences were not statistically
significant (Figure S2D). Additionally, there was no positive or
negative correlation between Th17 and Treg cell numbers in
the same mice. Collectively, these data support that
F. nucleatum modulates the tumor-immune microenvironment
and results in the expansion of myeloid-derived immune cell
types that have been reported to promote tumor progression
(Qian and Pollard, 2010).Cell HosA Fusobacterium-Associated Human Colorectal Cancer
Gene Signature Is Shared and Validated in Mice
Given our findings of F. nucleatum-induced myeloid-derived cell
expansion in mouse intestinal tumors, we asked if there would
also be a similar immunological profile in human Fusobacte-
rium-associated colon tumor transcriptomic data. We utilized
a data set of deep transcriptome sequencing (i.e., RNA-seq)
of 133 colon tumors generated by The Cancer Genome Atlas
(Cancer Genome Atlas Network, 2012). These patients all had
colorectal cancer, including stages I–IV, and none of these
patients had IBD-associated colorectal cancer or a history of
IBD. All nonhuman sequencing reads were applied to PathSeq,
a computational tool that identifies and quantifies the abundance
of all bacteria present in each tumor (http://www.broadinstitute.
org/software/pathseq/; Kostic et al., 2011). By calculating the
Spearman’s rank correlation coefficient of the relative abun-
dance of Fusobacterium spp. transcripts with host gene expres-
sion in this data set, we identified a Fusobacterium-associated
human CRC gene expression signature. We found a correlation
of immune cell marker genes associated with TAM (CD209,
CD206/MRC1, IL6, IL8, and CXCL10), MDSC (CD33 and IL6),
and DC (CD11c/ITGAX, CD209, TNF, and CD80), with
Fusobacterium abundance in human Fusobacterium-associated
tumors, by RNA-seq, similar to our findings with Fusobacterium
in mouse flow cytometry experiments (Figure 4A). Analysis using
the Ingenuity Pathway Analysis (IPA) gene ontology module re-
vealed that the Fusobacterium-associated human CRC gene
expression signature was highly enriched for the inflammatory
response gene ontology category (corrected p < 1 3 1033;
IPA) as well as other categories also related to immune and in-
flammatory disease (Figure 4B). To test the specificity of this cor-
relation, we performed the same analysis with the other top four
highly abundant genera besides Fusobacterium (Bacteroides,
Escherichia, Streptococcus, and Propionobacterium), but none
of these other genera were associated with enrichment for
inflammation-related gene functions, nor were they associated
with comparably high gene ontology enrichments in any other
functional categories (Figure S3). The relative abundance of
Fusobacterium spp. transcripts are shown for each of the 133
TCGA colon tumors with scaled expression values for the top
50 ranked genes denoted as the row ‘‘Z score’’ in the heatmap
(Figure 4C). Many of the top-ranked Fusobacterium-associated
genes, PTGS2 (COX-2), IL1b, IL6, IL8, and TNF (TNF-a), have
not only been investigated in colorectal carcinogenesis, but
also are induced by Fusobacterium in coculture with human
and mouse cell lines in vitro (Dharmani et al., 2011; Trinchieri,
2012).
The expression signature, notable for PTGS2 (COX-2), IL1b,
IL6, IL8, TNF (TNF-a), and MMP3, was suggestive of
an NF-kB-driven proinflammatory response (Hayden and
Ghosh, 2012 and http://www.bu.edu/nf-kb/gene-resources/
target-genes/) As NF-kB has been identified as a central link
between inflammation and cancer (DiDonato et al., 2012), we
assessed whether there was a correlation between increased
NF-kB activation and Fusobacterium abundance in human colo-
rectal cancers. We obtained freshly resected human colorectal
cancer samples and generated nuclear extracts from these sam-
ples. After stratifying the samples by their abundance of Fuso-
bacterium spp., we performed western blots on the nucleart & Microbe 14, 207–215, August 14, 2013 ª2013 Elsevier Inc. 211
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Figure 4. A Fusobacterium-Associated Human Colorectal Cancer Gene Signature Is Shared and Validated in Mice
(A) Immune cell types enriched in Fusobacterium-associatedmouse tumors are shownwith the humanmarker gene utilized to determine abundance in the TCGA
CRC RNA-seq data set.
(B) IPA biological function gene ontology categories enriched for Fusobacterium abundance-correlating gene sets are shown.
(C) Fusobacterium spp. transcript relative abundance is plotted for the 133 TCGAcolon tumors (upper panel and lower panel x axis), and scaled expression values
for the top 50 ranked genes denoted as the row Z score (y axis) are shown in a heatmap (lower panel) with a purple (low expression)–yellow (high expression) color
scale.
(D) Western blot of nuclear extracts from human colon cancer with a high or low Fusobacterium relative abundance. Fusobacterium relative abundance and
western blot densitometry are shown in the lower panel.
(E) qPCR analysis of a selection of the top 50 ranked genes in (B) in colon and small intestinal tumors from F. nucleatum- versus TSB-fed ApcMin/+mice. Data are
represented as mean ± SEM. Tumors from 6–9 mice per group were used. See also Figure S3.
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Fusobacterium Potentiates Intestinal Tumorigenesisextracts from Fusobacterium high and low tumors to examine
NF-kB activation. NF-kB was indeed more activated (increased
nuclear translocation of the p65 NF-kB subunit) in tumors with
a high, versus low, Fusobacterium abundance (Figure 4D).
Both Fusobacterium relative abundance (lower left panel) and
the densitometry ratio of NF-kB to laminB1 (lower right panel)
for each individual’s tumor are shown.
While our RNA sequencing and immunoblotting analyses sug-
gested a strong association between intratumoral Fusobacte-
rium abundance and specific immune pathways and genes, we
wanted to assess whether this association is direct by examining
gene expression patterns of small intestinal and colonic tumors
from ApcMin/+ mice exposed to F. nucleatum compared to
tumors from mice without Fusobacterium exposure. We found
that most of the mouse homologs of Fusobacterium-associated
proinflammatory genes identified in human tumors, including
Ptgs2 (COX-2 mouse homolog), Scyb1 (IL8 mouse homolog),212 Cell Host & Microbe 14, 207–215, August 14, 2013 ª2013 ElseviIl6, Tnf (TNFa), and Mmp3, were more highly expressed in both
small intestinal and colonic tumors from mice that were treated
with F. nucleatum compared to tumors from mice treated with
TSB (Figure 4E). In general, expression levels of these human
Fusobacterium-associated proinflammatory genes were higher
in the colonic tumors than small intestinal tumors; this may be
intrinsic to the anatomic site and related to the fact that the
gene list was derived from human colorectal cancer.
DISCUSSION
Entry of microbes andmicrobial products into the evolving tumor
microenvironment potentiates tumor growth by eliciting tumor-
promoting immune cell responses (Jobin, 2012). Our results
demonstrate that Fusobacterium spp., rare gut microbiome con-
stituents in the healthy human population (Segata et al., 2012),
are found at an increased abundance in the stool of patientser Inc.
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nomas and adenocarcinomas relative to noninvolved colonic tis-
sues. Introduction of F. nucleatum to ApcMin/+mice resulted in
accelerated small intestinal and colonic tumorigenesis, infiltra-
tion of specific myeloid cell subsets into tumors, and an NF-kB
proinflammatory signature. This proinflammatory signature was
sharedwith human colorectal cancer tissue with a high Fusobac-
terium abundance. Furthermore, in this issue of Cell Host &
Microbe, Rubinstein et al. (2013) show that clathrin-mediated
endocytosis of F. nucleatum, mediated via binding of the adhesin
molecule, FadA, to E-cadherin, results in downstream activation
of NF-kB (Rubinstein et al., 2013).
In contrast to other bacterial-drivenmodels of intestinal tumor-
igenesis (Arthur et al., 2012; Wu et al., 2009), we have found a
specific bacterial strain that accelerates intestinal tumorigenesis
in the absence of colitis. While ApcMin/+ mice fed F. nucleatum
exhibited enhanced intestinal tumorigenesis, neither Il10/ nor
T-bet/ 3 Rag2/ mouse models of colitis showed acceler-
ated tumorigenesis or exacerbated colitis upon introduction of
F. nucleatum. This may suggest that the tumorigenic effects of
fusobacteria operate downstream of the loss of the tumor sup-
pressor APC and the resulting intestinal dysplasia that occurs
in ApcMin/+ mice. This is relevant to most cases of human CRC,
as only 2% of CRC cases are linked to colitis, but greater than
80% of nonhypermutated CRC tumors bear APC mutations
(Cancer Genome Atlas Network, 2012). Our Fusobacterium find-
ings are also relevant to adenomas because mutations in APC
are among the earliest molecular alterations that occur in an
epithelium as it transitions to become an adenoma (Cho and Vo-
gelstein, 1992). Therefore, early tumor-initiating somatic muta-
tions likely precede the tissue enrichment of Fusobacterium
spp. This notion is also supported by the findings in Rubinstein
et al. (2013) that F. nucleatum stimulated proliferation only in
CRC cell lines, but not in a non-neoplastic cell line (Rubinstein
et al., 2013). Thesemutationsmay contribute to the development
of epithelial barrier defects, featuring the loss of tight junctions,
cell-to-cell contacts, epithelial polarity, and the mucus layer (Gri-
vennikov et al., 2012). Intestinal barrier defects at local sites of
dysplasia may promote the infiltration of Fusobacterium spp.,
among other bacteria and microbial products, allowing fusobac-
teria to take up residence in the tumor environment. This may
represent a crucial stage in colorectal neoplasia wherein myeloid
cell-mediated immune responses provide the driving force for
inflammatory genotoxic and epigenetic changes that lead to
cancer.
Although barrier defects expose the intestinal mucosa to the
entire luminal microbial milieu, Fusobacterium spp. become
the most highly enriched bacterium in colorectal tumors relative
to adjacent tissue (Castellarin et al., 2012; Kostic et al., 2012;
Tjalsma et al., 2012). This enrichment may be attributable to
the strong adhesive and invasive abilities of fusobacteria for
epithelial cells (Han et al., 2000; Strauss et al., 2011). The tumor
enrichment may also result from the growth advantage that fuso-
bacteria provide to the tumor by eliciting protumorigenic
responses from myeloid immune cells. Alternatively, metabolic
specializations may endow fusobacteria with a competitive
advantage in the evolving tumor milieu. Fusobacterium nuclea-
tum is an asaccharolytic bacterium; therefore, unlike the Entero-
bacteriaceae, it will not compete for glucose, a preferred sub-Cell Hosstrate for tumor metabolism (Vander Heiden et al., 2009).
Instead, fusobacteria can utilize amino acids and peptides as
nutrient sources in the tumor microenvironment. Products of
amino acid metabolism generated by fusobacteria, including
formyl-methionyl-leucyl-phenylalanine and short-chain fatty
acids, are myeloid cell chemoattractants, which may explain
the intratumoral myeloid cell expansion we observed and inter-
connect tumor metabolism, bacterial metabolism, and immune
cell function within the tumor microenvironment.
In addition, F. nucleatum strains, unlike many strict anaerobes
of the intestinal lumen, possess a rudimentary electron transport
chain, endowing them with a limited ability to respire oxygen
(Kapatral et al., 2002). Thus, F. nucleatummay be able to persist
and slowly replicate in the hypoxic tumor microenvironment. Ad-
hesive molecules that contribute to invasiveness in F. nucleatum
can promote bacterial aggregation and biofilm formation that
also enhance oxygen tolerance (Gursoy et al., 2010). Products
of fusobacterial metabolism may make the tumor microenviron-
ment more tumor permissive over time by directly promoting
tumor cell proliferation, blood vessel growth, or immune cell
infiltration.
We have shown that, in both human and mouse intestinal
tumors, the proinflammatory gene expression signature associ-
ated with Fusobacterium features the upregulation of PTGS2.
Epidemiological and clinical data suggest that nonsteroidal
anti-inflammatory drugs (NSAIDs) may be effective as a primary
and secondary preventative measure in colorectal neoplasia
(Chan et al., 2012). Our findings on Fusobacterium spp. and
the intrinsic inflammation that they elicit may further explain
why anti-inflammatory strategies such as NSAIDs are an effec-
tive colorectal cancer prevention strategy.
If our results demonstrating that fusobacteria potentiate
tumorigenesis can be extended to human CRC, then targeted
reduction of Fusobacterium populations in the oral cavity where
they are most abundant (Human Microbiome Project Con-
sortium, 2012), or in the gastrointestinal tract, may work to delay
or prevent tumor progression for patients at an increased risk for
CRC. These findings suggest that it will be important to consider
the contribution of members of the tumor microbiota, such as
Fusobacterium nucleatum, and the intersection between micro-
bial gene function and the host response in order to understand
colorectal cancer risk, development, and progression.
EXPERIMENTAL PROCEDURES
Bacterial Strains and Culturing
F. nucleatum (EAVG_002; 7/1) (Strauss et al., 2011) was a gift from the labora-
tory of E. Allen-Vercoe (University of Guelph). Streptococcus species were iso-
lated from freshly resected human colon tissues. Please see Supplemental
Experimental Procedures for additional information on bacterial identification
methods and culturing techniques.
Mice
All mice (C57BL/6-ApcMin/+, BALB/c Il-10/, and BALB/c T-bet/ 3
Rag2/) were maintained in the barrier facility at the Harvard School of Public
Health (HSPH), and all experimentation was carried out in accordance with
institutional guidelines. ApcMin/+mice were initially ordered from Jackson Lab-
oratory and then bred at HSPH.
Bacterial feeding experiments were performed for a period of 8 weeks,
beginning at 6 weeks of age. Bacteria were fed at 108 colony-forming units
(cfu) per day. Sham treatment consisted of TSB.t & Microbe 14, 207–215, August 14, 2013 ª2013 Elsevier Inc. 213
Cell Host & Microbe
Fusobacterium Potentiates Intestinal TumorigenesisHistopathology
Colons and small intestines were prepared for histologic analysis and
assessed for colitis or enteritis as previously described (Garrett et al., 2007).
Adenomas and adenocarcinomaswere counted in colons, and small intestines
were submitted in their entirety. ACF were identified in the same paraffin
sections as foci of 1–3 crypts in flat mucosa showing increased size as well
as nuclear enlargement and hyperchromasia.
Human Specimen Collection
Please see Supplemental Experimental Procedures for details on colonic
adenocarcinoma, adenomas, and stool samples.
DNA Preparation and Bacterial Quantification by qPCR
DNA preparation and qPCR of human and mouse tissues or stools are
described in detail in the Supplemental Experimental Procedures.
RNA Preparation and Gene Expression by qPCR
Total RNA was extracted using the RNeasy Kit (QIAGEN), DNase treated with
the DNA-free Kit (Ambion), and cDNA was generated using the iScript cDNA
Synthesis Kit (Bio-Rad). Relative gene expression was calculated using the
DDCT method. Primers were designed using MGH PrimerBank: http://pga.
mgh.harvard.edu/primerbank/.
Microbial FISH Analysis
Microbial FISH was performed as described (Kostic et al., 2012).
RNA-Seq Processing and Analysis
All primary sequence data on colonic adenoma (COAD) samples (https://
tcga-data.nci.nih.gov/docs/publications/coadread_2012/) were downloaded
from The Cancer Genome Atlas via dbGaP and the Data Coordinating Center
(http://cancergenome.nih.gov/). For additional details, please see the Supple-
mental Experimental Procedures.
Detection of NF-kB Activation
Fresh or fresh-frozen colon tumor tissue (20–80 mg per sample) was pro-
cessed for nuclear protein isolation with the NE-PER Kit (Thermo Scientific).
Protein lysates were resolved and transferred to polyvinylidene fluoride
(PVDF) membrane, and blots were probed with antibodies directed against
p65 and lamin B1 (Cell Signaling Technology). Samples were stratified as
Fusobacterium high (qPCR Fusobacterium abundance greater than 40.0,
calculated as 1.8^[CT< Fusobacterium>  CT< Eubacteria>] 3 1,000, or
16S sequencing Fusobacterium abundance greater than 0.25, calculated as
described in Kostic et al., 2012) or Fusobacterium low (qPCR Fusobacterium
abundance less than 1.0, or 16S sequencing Fusobacterium abundance less
than 0.015). Western blot densitometry analysis was performed using ImageJ
software (http://rsbweb.nih.gov/ij/)
Isolation of Intestinal Tumor-Infiltrating Cells
Small intestine was removed, opened, and washed with Ca+- and Mg+-free
Dulbecco’s phosphate-buffered saline (DPBS). Tumors were dissected,
weighed, minced, and incubated in Hank’s balanced salt solution (HBSS)
with 0.1 mg/ml collagenase D (Roche), 50 U/ml DNase I (Roche), and
50 mg/mg dispase (StemCell Technologies) for 30min at 37C. Single-cell sus-
pensions were resuspended in cell-staining solution (PBS with 2% fetal calf
serum [FCS]) for flow cytometry.
Multicolor Flow Cytometry
Cells were incubated with Fc blocking antibody (BioLegend) and stained with
fluorochrome-conjugated monoclonal antibodies of cell-surface markers. An-
tibodies and clone information are provided in the Supplemental Experimental
Procedures.
Expression of B220 (clone RA3-6B2) and PDCA-1 (clone 927) was also
examined. These two antigens on CD11c low-expressing cells are used to
identify plasmacytoid DCs. However, cell numbers were very low in tumors
(average 2 3 103 cells/gram of tumor with a range from 0–16 3 103 cells/
gram of tumor in F. nucleatum-treated mice). Thus, these data are not shown.214 Cell Host & Microbe 14, 207–215, August 14, 2013 ª2013 ElseviProcedures describing intracellular staining for IL-17A, Foxp3, arginase-1,
and iNOS and cell sorting are provided in the Supplemental Experimental
Procedures.
In Vitro T Cell Suppression Assay
Splenic CD3ε+CD4+ T cells were sorted from ApcMin/+ mice and labeled with
CellTrace Violet (Invitrogen) according to manufacturer’s instructions. Labeled
CD3ε+CD4+ T cells were plated at 2 3 105 cells/well with sorted MDSCs,
TAMs, and M2-like TAMs (2 3 105) in the presence of 1 mg/ml anti-CD3 anti-
body and 1 mg/ml anti-CD28 antibody. After 72 hr, cells were collected and
analyzed by flow cytometry.
Statistical Analysis
Generally, data are displayed in dot-plot format, with the center line indicating
the mean and SEM represented by the error bars. All two-group comparisons
were performed using the nonparametric Mann-Whitney U test, except for Fig-
ure 1A, for which the nonparametric Wilcoxon matched-pairs signed-rank test
was performed. For RNA-seq data, genus relative abundance was correlated
to host gene expression using the Spearman’s rank correlation coefficient, and
corrected p values were obtained by correcting for multiple hypothesis testing
using the false discovery rate method. Statistical analysis for Table S1 was
performed using Fisher’s exact test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.chom.2013.07.007.
ACKNOWLEDGMENTS
We thank members of the Garrett and Meyerson labs for discussions and E.
Allen-Vercoe for Fusobacterium strains and culturing advice. Adenomas and
matched normal tissue samples were provided by the Cooperative Human
Tissue Network, a NCI-supported resource. These studies were supported
by R01CA154426 (NCI), K08AI078942 (NIAID), a Burroughs Wellcome Career
in Medical Sciences Award, a Searle Scholars Award, and a Cancer Research
Institute Investigator Award to W.S.G.; U54HG003067 (National Genome
Research Institute), P50CA127003 (NCI), RC2CA148317 (NCI),
R01CA154426 (NCI), and a Starr Cancer Consortium Award to M. Meyerson,
and P50CA127003 (SPORE) to C.S.F.
Received: February 25, 2013
Revised: May 29, 2013
Accepted: June 21, 2013
Published: August 14, 2013
REFERENCES
Arthur, J.C., Perez-Chanona, E., Mu¨hlbauer, M., Tomkovich, S., Uronis, J.M.,
Fan, T.J., Campbell, B.J., Abujamel, T., Dogan, B., Rogers, A.B., et al. (2012).
Intestinal inflammation targets cancer-inducing activity of the microbiota.
Science 338, 120–123.
Cancer Genome Atlas Network. (2012). Comprehensive molecular character-
ization of human colon and rectal cancer. Nature 487, 330–337.
Castellarin, M., Warren, R.L., Freeman, J.D., Dreolini, L., Krzywinski, M.,
Strauss, J., Barnes, R., Watson, P., Allen-Vercoe, E., Moore, R.A., and Holt,
R.A. (2012). Fusobacterium nucleatum infection is prevalent in human colo-
rectal carcinoma. Genome Res. 22, 299–306.
Chan, A.T., Arber, N., Burn, J., Chia, W.K., Elwood, P., Hull, M.A., Logan, R.F.,
Rothwell, P.M., Schro¨r, K., and Baron, J.A. (2012). Aspirin in the chemopreven-
tion of colorectal neoplasia: an overview. Cancer Prev. Res. (Phila.) 5,
164–178.
Cho, K.R., and Vogelstein, B. (1992). Genetic alterations in the adenoma—car-
cinoma sequence. Cancer 70(Suppl ), 1727–1731.
Human Microbiome Project Consortium. (2012). Structure, function and diver-
sity of the healthy human microbiome. Nature 486, 207–214.er Inc.
Cell Host & Microbe
Fusobacterium Potentiates Intestinal TumorigenesisCoombes, J.L., Siddiqui, K.R., Arancibia-Ca´rcamo, C.V., Hall, J., Sun, C.M.,
Belkaid, Y., and Powrie, F. (2007). A functionally specialized population of
mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and
retinoic acid-dependent mechanism. J. Exp. Med. 204, 1757–1764.
Coussens, L.M., and Pollard, J.W. (2011). Leukocytes in mammary develop-
ment and cancer. Cold Spring Harb. Perspect. Biol. 3, 3.
Dharmani, P., Strauss, J., Ambrose, C., Allen-Vercoe, E., and Chadee, K.
(2011). Fusobacterium nucleatum infection of colonic cells stimulates MUC2
mucin and tumor necrosis factor alpha. Infect. Immun. 79, 2597–2607.
DiDonato, J.A., Mercurio, F., and Karin, M. (2012). NF-kB and the link between
inflammation and cancer. Immunol. Rev. 246, 379–400.
Gabrilovich, D.I., and Nagaraj, S. (2009). Myeloid-derived suppressor cells as
regulators of the immune system. Nat. Rev. Immunol. 9, 162–174.
Gabrilovich, D.I., Ostrand-Rosenberg, S., and Bronte, V. (2012). Coordinated
regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253–268.
Garrett, W.S., Lord, G.M., Punit, S., Lugo-Villarino, G., Mazmanian, S.K., Ito,
S., Glickman, J.N., and Glimcher, L.H. (2007). Communicable ulcerative colitis
induced by T-bet deficiency in the innate immune system. Cell 131, 33–45.
Garrett, W.S., Punit, S., Gallini, C.A., Michaud, M., Zhang, D., Sigrist, K.S.,
Lord, G.M., Glickman, J.N., andGlimcher, L.H. (2009). Colitis-associated colo-
rectal cancer driven by T-bet deficiency in dendritic cells. Cancer Cell 16,
208–219.
Grivennikov, S.I., Wang, K., Mucida, D., Stewart, C.A., Schnabl, B., Jauch, D.,
Taniguchi, K., Yu, G.-Y., O¨sterreicher, C.H., Hung, K.E., et al. (2012).
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-
mediated tumour growth. Nature 491, 254–258.
Gursoy, U.K., Po¨lla¨nen, M., Ko¨no¨nen, E., and Uitto, V.J. (2010). Biofilm forma-
tion enhances the oxygen tolerance and invasiveness of Fusobacterium nucle-
atum in an oral mucosa culture model. J. Periodontol. 81, 1084–1091.
Han, Y.W., Shi, W., Huang, G.T.J., Kinder Haake, S., Park, N.-H., Kuramitsu,
H., and Genco, R.J. (2000). Interactions between periodontal bacteria and
human oral epithelial cells: Fusobacterium nucleatum adheres to and invades
epithelial cells. Infect. Immun. 68, 3140–3146.
Hayden, M.S., and Ghosh, S. (2012). NF-kB, the first quarter-century: remark-
able progress and outstanding questions. Genes Dev. 26, 203–234.
Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., and Forman, D. (2011).
Global cancer statistics. CA Cancer J. Clin. 61, 69–90.
Jobin, C. (2012). Colorectal cancer: CRC—all about microbial products and
barrier function? Nat Rev Gastroenterol Hepatol 9, 694–696.
Josefowicz, S.Z., Lu, L.-F., and Rudensky, A.Y. (2012). Regulatory T cells:
mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531–564.
Kapatral, V., Anderson, I., Ivanova, N., Reznik, G., Los, T., Lykidis, A.,
Bhattacharyya, A., Bartman, A., Gardner, W., Grechkin, G., et al. (2002).
Genome sequence and analysis of the oral bacterium Fusobacterium nuclea-
tum strain ATCC 25586. J. Bacteriol. 184, 2005–2018.
Kostic, A.D., Ojesina, A.I., Pedamallu, C.S., Jung, J., Verhaak, R.G.W., Getz,
G., and Meyerson, M. (2011). PathSeq: software to identify or discover mi-
crobes by deep sequencing of human tissue. Nat. Biotechnol. 29, 393–396.
Kostic, A.D., Gevers, D., Pedamallu, C.S., Michaud, M., Duke, F., Earl, A.M.,
Ojesina, A.I., Jung, J., Bass, A.J., Tabernero, J., et al. (2012). Genomic analysis
identifies association of Fusobacterium with colorectal carcinoma. Genome
Res. 22, 292–298.
Mantovani, A., and Sica, A. (2010). Macrophages, innate immunity and cancer:
balance, tolerance, and diversity. Curr. Opin. Immunol. 22, 231–237.Cell HosMantovani, A., Cassatella, M.A., Costantini, C., and Jaillon, S. (2011).
Neutrophils in the activation and regulation of innate and adaptive immunity.
Nat. Rev. Immunol. 11, 519–531.
Marchesi, J.R., Dutilh, B.E., Hall, N., Peters,W.H.M., Roelofs, R., Boleij, A., and
Tjalsma, H. (2011). Towards the human colorectal cancer microbiome. PLoS
ONE 6, e20447.
McCoy, A.N., Arau´jo-Pe´rez, F., Azca´rate-Peril, A., Yeh, J.J., Sandler, R.S., and
Keku, T.O. (2013). Fusobacterium is associated with colorectal adenomas.
PLoS ONE 8, e53653.
Mellman, I., Coukos, G., and Dranoff, G. (2011). Cancer immunotherapy
comes of age. Nature 480, 480–489.
Qian, B.-Z., and Pollard, J.W. (2010). Macrophage diversity enhances tumor
progression and metastasis. Cell 141, 39–51.
Rubinstein, M.R., Wang, X., Liu, W., Hao, Y., Cai, G., and Han, Y.W. (2013).
Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating
E-cadherin/b-catenin signaling via its FadA adhesin. Cell Host Microbe 14, this
issue, 195–206.
Ruffell, B., Affara, N.I., and Coussens, L.M. (2012). Differential macrophage
programming in the tumor microenvironment. Trends Immunol. 33, 119–126.
Sanapareddy, N., Legge, R.M., Jovov, B., McCoy, A., Burcal, L., Araujo-Perez,
F., Randall, T.A., Galanko, J., Benson, A., Sandler, R.S., et al. (2012). Increased
rectal microbial richness is associated with the presence of colorectal ade-
nomas in humans. ISME J. 6, 1858–1868.
Scanlan, P.D., Shanahan, F., Clune, Y., Collins, J.K., O’Sullivan, G.C.,
O’Riordan, M., Holmes, E., Wang, Y., and Marchesi, J.R. (2008). Culture-inde-
pendent analysis of the gut microbiota in colorectal cancer and polyposis.
Environ. Microbiol. 10, 789–798.
Segata, N., Haake, S.K., Mannon, P., Lemon, K.P., Waldron, L., Gevers, D.,
Huttenhower, C., and Izard, J. (2012). Composition of the adult digestive tract
bacterial microbiome based on sevenmouth surfaces, tonsils, throat and stool
samples. Genome Biol. 13, R42.
Shen, X.J., Rawls, J.F., Randall, T., Burcal, L., Mpande, C.N., Jenkins, N.,
Jovov, B., Abdo, Z., Sandler, R.S., and Keku, T.O. (2010). Molecular character-
ization of mucosal adherent bacteria and associations with colorectal ade-
nomas. Gut Microbes 1, 138–147.
Strauss, J., Kaplan, G.G., Beck, P.L., Rioux, K., Panaccione, R., Devinney, R.,
Lynch, T., and Allen-Vercoe, E. (2011). Invasive potential of gut mucosa-
derived Fusobacterium nucleatum positively correlates with IBD status of
the host. Inflamm. Bowel Dis. 17, 1971–1978.
Tjalsma, H., Boleij, A., Marchesi, J.R., and Dutilh, B.E. (2012). A bacterial
driver-passenger model for colorectal cancer: beyond the usual suspects.
Nat. Rev. Microbiol. 10, 575–582.
Trinchieri, G. (2012). Cancer and inflammation: an old intuition with rapidly
evolving new concepts. Annu. Rev. Immunol. 30, 677–706.
Uronis, J.M., Mu¨hlbauer, M., Herfarth, H.H., Rubinas, T.C., Jones, G.S., and
Jobin, C. (2009). Modulation of the intestinal microbiota alters colitis-associ-
ated colorectal cancer susceptibility. PLoS ONE 4, e6026.
Vander Heiden, M.G., Cantley, L.C., and Thompson, C.B. (2009).
Understanding the Warburg effect: the metabolic requirements of cell prolifer-
ation. Science 324, 1029–1033.
Wu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso,
D.L., Brancati, F.L., Wick, E., McAllister, F., et al. (2009). A human colonic
commensal promotes colon tumorigenesis via activation of T helper type 17
T cell responses. Nat. Med. 15, 1016–1022.t & Microbe 14, 207–215, August 14, 2013 ª2013 Elsevier Inc. 215
